# SLV213 Treatment in Ambulatory COVID-19 Patients

> **NCT04843787** · PHASE2 · UNKNOWN · sponsor: **Kenneth Krantz, MD, PhD** · enrollment: 81 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** SLV213
- **DRUG:** SLV213
- **DRUG:** SLV213
- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04843787
- **Lead sponsor:** Kenneth Krantz, MD, PhD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-01
- **Primary completion:** 2024-06-01
- **Final completion:** 2024-07-01
- **Target enrollment:** 81 (ESTIMATED)
- **Last updated:** 2023-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843787, "SLV213 Treatment in Ambulatory COVID-19 Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04843787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*